These results support that sotorasib can be given together with strong CYP3A4 and OATP1B1/3 inhibitors but the co鈥恆dministration of sotorasib and strong CYP3A4 inducers should be avoided.Cardona, PanliDutta, SandeepHouk, BrettClinical Pharmacology in Drug Development...
In conclusion, ACT‐1004‐1239 is classified as a moderately sensitive CYP3A4 substrate (i.e., increase of AUC ≥2‐ to <5‐fold), and this should be considered in further clinical studies if CYP3A4 inhibitors are concomitantly administered.Huynh, Christine...
reduction in patients administered dual strong inhibitors of p-glycoprotein (P-gp) and cytochrome P-450 (CYP) 3A4, there are limited published data regarding potential drug-drug interactions between apixaban (Eliquis) and common p-glycoprotein (P-gp) and CYP3A4 inhibitors co-administered with ...